Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR T Cells as Consolidation for Older Adults With ALL in First Remission
NCT05707273Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Apr 2023
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLIC-1901 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by City of Hope. Primary endpoints: Incidence of dose-limiting toxicity at 28 days and Incidence of adverse events at 15 years. Started Apr 2023; status: active, not recruiting.
02
Drugs
CLIC-1901
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05707273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707273.